ICyte Facilitates First-Time Launch of Innovative Psychiatric Therapy

IntegriChain was approached by a customer that was planning to launch a novel, oral therapy targeting 2.4 million patients in the highly generalized and competitive antipsychotic therapy segment. To bring its therapy to market, they would need to contract with both Medicaid and Medicare programs as well as enter into complex contracts with wholesalers and group purchasing organizations (GPOs). However, the COVID pandemic made this very difficult and the leadership team was struggling with how they could be truly ready for their first launch and have an infrastructure capable of supporting a changing virtual-selling landscape and provide scale for future therapies. Learn more by downloading the case study. Download below!